Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Phase 1

Completed

• Conditions: Schizophrenia
• Interventions: Drug: MK2637

• Registration Number: NCT00934466
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2009-07-06
• Study First Submitted QC: 2009-07-07
• Study First Posted: 2009-07-08
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-23
• Last Update Posted: 2015-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

• Subject is right-handed
• Subject is in good health
• Subject is a nonsmoker

Exclusion Criteria

• Subject works a night shift
• Subject has a history of any illness that might make participation in the study unsafe or confound the study results
• Subject has a history of head injury

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	MK2637	MK2637 120 mg

Primary Outcome Measures

Name	Time	Method
Increase in Motor Evoked Potential (MEP) after dosing with dextromethorphan compared to placebo	5 Hours after initial dosing
Increase in amplitude in the gamma frequency band (24-60 Hz) of resting qEEG after dosing with dextromethorphan compared to placebo	4 Hours after initial dosing

Secondary Outcome Measures

Name	Time	Method
Change in Motor Evoked Potential (MEP) after dosing with MK2637 as compared to placebo	5 hours after initial dosing
Increase in amplitude in the theta frequency band (4-8 Hz) of resting qEEG after dosing with MK2637 compared to placebo	6.5 hours after initial dosing